跳转至内容
Merck
CN

10831

Histopaque®-1083

sterile-filtered, density: 1.083

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.75
UNSPSC Code:
12352207
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


sterility

sterile-filtered

Quality Level

form

liquid

shelf life

Expiry date on the label.

technique(s)

cell culture | mammalian: suitable

impurities

endotoxin, tested

density

1.083

application(s)

hematology
histology

storage temp.

2-8°C

General description

Histopaque®-1083是一种含有聚蔗糖和泛影酸钠的溶液,密度调整至1.083 g/mL。它有助于从大鼠、小鼠和其他小型哺乳动物的少量血液中分离活的单核细胞。

Application

Histopaque®-1083用于从大鼠外周血中分离单核细胞和白细胞。

Biochem/physiol Actions

将抗凝血液铺在HISTOPAQUE1083上。离心时,红细胞被聚多糖聚集并迅速沉淀,而淋巴细胞和其他单个核细胞保留在血浆-HISTOPAQUE1083分界面。红细胞会沉淀到离心管的底部。

Features and Benefits

Histopaque®-1083 有许多优势,比如:

  • 可使活细胞极佳恢复
  • 允许选择分离不同种类的血细胞
  • 防止细胞变形
  • 保持细胞活力
  • 最小化外来细胞干扰
  • 各批次性能可重复
  • 经过过滤杀菌和内毒素检测
  • 在 2-8°C 避光保护条件下可稳定保存至少2年

Legal Information

Histopaque is a registered trademark of Merck KGaA, Darmstadt, Germany


pictograms

Corrosion

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter

存储类别

10 - Combustible liquids



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


实验方案

Ficoll 400®是由蔗糖和环氧氯丙烷共聚而成的一种高度分支化的聚合物。Ficoll 400®是完全非离子性的。由于其含有丰富的羟基,Ficoll 400®具有很强的亲水性和水溶性。

本疑难排查指南针对使用 Histopaque 时观察到的最常见错误来源提出解决方案,但这并不代表本指南是全面无遗的。

Ficoll 400® is a non-ionic polymer with high hydrophilicity and water solubility, suitable for various biological applications.

查看所有协议

商品

我们提供完整的密度梯度介质产品线,用于分离或提取白细胞、病毒、DNA、RNA、细胞器以及许多其他应用。我们的产品线包括用于在研究实验室中分离白细胞的Histopaque®碘化梯度介质,用于哺乳动物细胞分离的多糖介质,用于哺乳动物细胞和细胞器分离的胶体二氧化硅介质,以及用于DNA、病毒和蛋白质分离的无机盐介质。

Centrifugation enables the separation of particles by sedimentation. Learn how to separate particles using a centrifuge and how to use Stokes' law to calculate the velocity of sedimentation.


Bella S Guerrouahen et al.
Pediatric blood & cancer, 53(6), 1132-1135 (2009-06-02)
Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. Greater use of targeted therapies should involve
Jennifer J Chung et al.
The Journal of thoracic and cardiovascular surgery, 159(5), 1825-1835 (2019-07-30)
Extracellular vesicles (EVs) are promising therapeutics for cardiovascular disease, but poorly-timed delivery might hinder efficacy. We characterized the time-dependent response to endothelial progenitor cell (EPC)-EVs within an injectable shear-thinning hydrogel (STG+EV) post-myocardial infarction (MI) to identify when an optimal response
Nagsen Gautam et al.
Journal of pharmaceutical and biomedical analysis, 153, 248-259 (2018-03-09)
Nucleoside reverse transcriptase inhibitors (NRTIs) require intracellular phosphorylation to active triphosphate (TP) nucleotide metabolites before they can inhibit the HIV reverse transcriptase. However, monitoring these pharmacologically active TP metabolites is challenging due to their instability and their low concentrations at



全球贸易项目编号

货号GTIN
39075-250MG-F04061832808826
39075-50MG-F04061832808833
294721-1G04061826601457
10831-100ML04061838682673
10831-6X100ML04061838682826